Australian budget hits device and diagnostics industries
This article was originally published in Clinica
A restructuring of the product approval fee schedule is expected in Australia following the presentation of the 1996/97 federal budget on August 20th. The Therapeutic Goods Administration aims to achieve 75% cost recovery from industry by 1998/99 and will increase fees in phases as follows:
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.